Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03040024 · ClinicalTrials.gov registry record · Phase 4
Delirium Prevention With Ketamine in Ear, Nose, and Throat (ENT) Patients
A Phase 4 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 71
- Enrollment target
NCT03040024 is a Phase 4 study that was terminated before completion, run by Emory University. The registered enrollment target is 71 participants.
The verdict
NCT03040024, a Phase 4 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 71 participants
- Enrollment target
Study Summary
The goal of this prospective randomized double blinded placebo controlled study is to investigate if a single dose of ketamine in addition to standard anesthesia will reduce the risk of delirium in otolaryngeal cancer patients postoperatively. Ketamine's effect on post-operative pain and opioid use will be measured as well. Electroencephalogram (EEG) will be utilized during the surgical procedure to evaluate its potential as a possible predictive device for delirium.
Interventions
- DRUG Placebo
- DRUG Ketamine
- DEVICE Electroencephalogram (EEG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2017-03-17 |
| Est. Completion | 2020-04-24 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03040024
The ClinicalTrials.gov registry entry for NCT03040024 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03040024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03040024 about?
NCT03040024 is a clinical study titled "Delirium Prevention With Ketamine in Ear, Nose, and Throat (ENT) Patients". The goal of this prospective randomized double blinded placebo controlled study is to investigate if a single dose of ketamine in addition to standard anesthesia will reduce the risk of delirium in otolaryngeal cancer patients postoperatively. Ketamine's effect on post-operative pain and opioid use ...
What is the current status of trial NCT03040024?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 71 participants. The study started on 2017-03-17. Estimated completion is 2020-04-24.
What interventions are being tested in trial NCT03040024?
The interventions under investigation include: Placebo (DRUG), Ketamine (DRUG), Electroencephalogram (EEG) (DEVICE).
Who is sponsoring clinical trial NCT03040024?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.